Clinical trials of MRS methods

Margarida Julia-Sape; Fernando Arias-Mendoza; John R. Griffiths

doi:10.1002/9780470034590.emrstm1474

Clinical trials of MRS methods

Margarida Julia-Sape^*, Fernando Arias-Mendoza, John R. Griffiths

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

2 Citations (Scopus)

Abstract

© 2015 John Wiley & Sons, Ltd. In order to determine the applicability of noninvasive magnetic resonance spectroscopy (MRS) to the study of a diseased tissue or organ in the human body, it is necessary to determine if MRS is safe and effective. This is usually the primary purpose of a clinical trial of a novel method. A clinical trial for MRS may also reveal which technical approach works best for the specific application and characteristics of the population being studied. In this article, we discuss the legal, ethical, and scientific requirements to be considered before the start of a clinical trial of an MRS protocol, as well as constraints that may arise during its execution. MRS-specific issues arising from a couple of successful clinical MRS trials for classifying brain tumors with 1H MRS (INTERPRET and eTUMOUR) and body tumors with 31P MRS (the Cooperative Group on MRS Application in Cancer, CoGMAC) serve as illustrative examples.

Original language	English
Pages (from-to)	779-788
Number of pages	10
Journal	eMagRes
Volume	4
Issue number	4
DOIs	https://doi.org/10.1002/9780470034590.emrstm1474
Publication status	Published - 1 Jan 2015

Keywords

artifacts
clinical trial
MRS
multicenter
quality control

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/9780470034590.emrstm1474

Cite this

@article{b0681b9d898c499c86d6c2c5ca31f0f1,

title = "Clinical trials of MRS methods",

abstract = "{\textcopyright} 2015 John Wiley & Sons, Ltd. In order to determine the applicability of noninvasive magnetic resonance spectroscopy (MRS) to the study of a diseased tissue or organ in the human body, it is necessary to determine if MRS is safe and effective. This is usually the primary purpose of a clinical trial of a novel method. A clinical trial for MRS may also reveal which technical approach works best for the specific application and characteristics of the population being studied. In this article, we discuss the legal, ethical, and scientific requirements to be considered before the start of a clinical trial of an MRS protocol, as well as constraints that may arise during its execution. MRS-specific issues arising from a couple of successful clinical MRS trials for classifying brain tumors with 1H MRS (INTERPRET and eTUMOUR) and body tumors with 31P MRS (the Cooperative Group on MRS Application in Cancer, CoGMAC) serve as illustrative examples.",

keywords = "artifacts, clinical trial, MRS, multicenter, quality control",

author = "Margarida Julia-Sape and Fernando Arias-Mendoza and Griffiths, {John R.}",

year = "2015",

month = jan,

day = "1",

doi = "10.1002/9780470034590.emrstm1474",

language = "English",

volume = "4",

pages = "779--788",

journal = "eMagRes",

issn = "2055-6101",

publisher = "Blackwell",

number = "4",

}

TY - JOUR

T1 - Clinical trials of MRS methods

AU - Julia-Sape, Margarida

AU - Arias-Mendoza, Fernando

AU - Griffiths, John R.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - © 2015 John Wiley & Sons, Ltd. In order to determine the applicability of noninvasive magnetic resonance spectroscopy (MRS) to the study of a diseased tissue or organ in the human body, it is necessary to determine if MRS is safe and effective. This is usually the primary purpose of a clinical trial of a novel method. A clinical trial for MRS may also reveal which technical approach works best for the specific application and characteristics of the population being studied. In this article, we discuss the legal, ethical, and scientific requirements to be considered before the start of a clinical trial of an MRS protocol, as well as constraints that may arise during its execution. MRS-specific issues arising from a couple of successful clinical MRS trials for classifying brain tumors with 1H MRS (INTERPRET and eTUMOUR) and body tumors with 31P MRS (the Cooperative Group on MRS Application in Cancer, CoGMAC) serve as illustrative examples.

AB - © 2015 John Wiley & Sons, Ltd. In order to determine the applicability of noninvasive magnetic resonance spectroscopy (MRS) to the study of a diseased tissue or organ in the human body, it is necessary to determine if MRS is safe and effective. This is usually the primary purpose of a clinical trial of a novel method. A clinical trial for MRS may also reveal which technical approach works best for the specific application and characteristics of the population being studied. In this article, we discuss the legal, ethical, and scientific requirements to be considered before the start of a clinical trial of an MRS protocol, as well as constraints that may arise during its execution. MRS-specific issues arising from a couple of successful clinical MRS trials for classifying brain tumors with 1H MRS (INTERPRET and eTUMOUR) and body tumors with 31P MRS (the Cooperative Group on MRS Application in Cancer, CoGMAC) serve as illustrative examples.

KW - artifacts

KW - clinical trial

KW - MRS

KW - multicenter

KW - quality control

UR - http://www.scopus.com/inward/record.url?scp=85021367075&partnerID=8YFLogxK

U2 - 10.1002/9780470034590.emrstm1474

DO - 10.1002/9780470034590.emrstm1474

M3 - Article

SN - 2055-6101

VL - 4

SP - 779

EP - 788

JO - eMagRes

JF - eMagRes

IS - 4

ER -

Clinical trials of MRS methods

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this